Á¤¹ÐÀÇ·á ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº CAGR 9.62%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2025³â 20¾ï 1,300¸¸ ´Þ·¯¿¡¼ 2030³â±îÁö´Â 31¾ï 8,600¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
Á¤¹ÐÀÇ·á´Â ¸ÂÃãÇü ÀÇ·á¶ó°íµµ ºÒ¸®´Â Áúº´ ¿¹¹æ ¹× Ä¡·á¿¡ ´ëÇÑ ¸ÂÃãÇü Á¢±Ù¹ýÀÔ´Ï´Ù. Áúº´¿¡ ´ëÇÑ °¡¿ë¼ºÀ» ¿¹ÃøÇϰí Áúº´ ÁøÇàÀ» ¿¹¹æÇÏ´Â µ¥ ÁßÁ¡À» µÎ°í ¾à¹° ó¹æÀÇ ½ÃÇà Âø¿À¸¦ ÁÙÀÌ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈÇÕ´Ï´Ù. Á¤¹ÐÀÇ·á ¼ÒÇÁÆ®¿þ¾î´Â µ¥ÀÌÅÍ Áß½ÉÀÇ °³ÀÎÈµÈ Ä¡·á¸¦ ȯÀÚ¿¡°Ô Á¦°øÇÏ´Â ±â¼ú Ç÷§Æû ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¾Ï ÀÌȯÀ²ÀÇ ¼¼°è »ó½ÂÀº ¿¹Ãø ±â°£ µ¿¾È Á¤¹ÐÀÇ·á ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿ä¼ÒÀÔ´Ï´Ù. Á¤¹ÐÀÇ·á´Â ȯÀÚ¿¡°Ô ¸ÂÃã Ä¡·á¸¦ Á¦°øÇÔÀ¸·Î½á ¾Ï Ä¡·á¿¡ ¸Å¿ì Áß¿äÇÑ ¿ëµµ¸¦ °¡Áö°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ÇコÄɾÀÇ ÀΰøÁö´É(AI)ÀÇ ÅëÇÕÀÌ ÁøÇàµÇ°í ÀÖ´Â °Íµµ, Á¤¹ÐÀÇ·á ¼ÒÇÁÆ®¿þ¾î ¼ö¿ä¸¦ ³ôÀÌ´Â Å« ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¼¼°è °¢±¹Àº ÇコÄÉ¾î ºÐ¾ß¿¡¼ AIÀÇ °³¹ß°ú ÅëÇÕÀ» °ÈÇϱâ À§ÇÑ Áß¿äÇÑ Á¤Ã¥°ú Àü·«À» ½Ç½ÃÇß½À´Ï´Ù.
Á¤¹ÐÀÇ·á ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ :
- ¼¼°è AI ±â¼úÀÇ Áøº¸ : ÀΰøÁö´É ±â¼úÀÇ ±Þ¼ÓÇÑ Áøº¸´Â Á¤¹ÐÀÇ·á ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀÇ È®´ë¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. AI ±â¼ú ºÐ¾ß´Â ±â¼ú Çõ½Å¿¡ ÈûÀÔ¾î ´ëÆøÀûÀÎ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ¹Ì±¹, ij³ª´Ù, Àεµ µî °¢±¹ Á¤ºÎ´Â ƯÈ÷ ÀÇ·á ºÐ¾ß¿¡¼ AI °³¹ßÀ» ÃËÁøÇϱâ À§ÇØ ´Ù¾çÇÑ Á¤Ã¥°ú ÀÌ´Ï¼ÅÆ¼ºê¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î, 2024³â 9¿ù, ÀεµÀÇ º¸°Ç°¡Á· º¹ÁöºÎ´Â IIT Ä·Ç® ¹× ±¹°¡º¸°Ç±¹°ú Çù·ÂÇÏ¿© ÇコÄɾ¼ AI ¾ÖÇø®ÄÉÀ̼ÇÀ» À§ÇÑ µðÁöÅÐ °ø°øÀ縦 °³¹ßÇÒ °ÍÀ̶ó°í ¹ßÇ¥Çß½À´Ï´Ù. ¸¶Âù°¡Áö·Î 2024³â 4¿ù ¿µ±¹ÀÇ ÀǾàǰ ¹× ÀÇ·á Á¦Ç° ±ÔÁ¦Ã»(MHRA)Àº AI¸¦ ÇコÄɾ ÅëÇÕÇϱâ À§ÇÑ Àü·«Àû Á¢±Ù¹ýÀ» ¹ßÇ¥Çß½À´Ï´Ù.
Á¤¹ÐÀÇ·á ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀ» Çü¼ºÇÏ´Â Áö¸®Àû µ¿Çâ :
- ºÏ¹ÌÀÇ ÇöÀúÇÑ ¼ºÀå : ¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì°¡ Á¤¹ÐÀÇ·á ¼ÒÇÁÆ®¿þ¾î ½ÃÀå¿¡¼ Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹°ú ij³ª´Ù¿Í °°Àº ±¹°¡µéÀº ÀΰøÁö´ÉÀ» ÀÇ·á ½Ã½ºÅÛ¿¡ ÅëÇÕÇϱâ À§ÇÑ Áß¿äÇÑ Àü·«À» ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. ¾ÏÀ» Æ÷ÇÔÇÑ ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â Á¤¹ÐÀÇ·á ±â¼ú ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇÕ´Ï´Ù.
ºÒ¾È, ¿ì¿ïÁõ, PTSD¿Í °°Àº Á¤½Å ÁúȯÀÇ ÀÌȯÀ²ÀÌ Áõ°¡Çϸé È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ±ä±ÞÇÑ Çʿ伺ÀÌ »ý±é´Ï´Ù. COVID-19ÀÇ À¯ÇàÀº ÀÌ·¯ÇÑ °úÁ¦¸¦ ¾ÇȽÃÄÑ °³ÀÎÀÌ ½ºÆ®·¹½º¿Í ºÒÈ®½Ç¼ºÀ» ³ôÀÌ´Â µ¥ µµ¿òÀ» ¿äûÇ߱⠶§¹®¿¡ Á¤½Å °Ç° ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇß½À´Ï´Ù. ¿ä¾àÇϸé, ½ÃÀå »óȲÀº AI ±â¼úÀÇ Áøº¸, ¸¸¼º Áúȯ¿¡ ´ëÇÑ È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä Áõ°¡, ÀÇ·á ±â¼ú Çõ½ÅÀ» ÃËÁøÇÏ´Â Á¤ºÎÀÇ Áö¿ø ¹æ¾È ¹× ÀÌ È®´ëµÇ´Â ½ÃÀå ȯ°æÀ» °ÈÇÏ´Â ºÏ¹Ì¸¦ Áß½ÉÀ¸·Î ÇÑ À¯¸®ÇÑ Áö¸®Àû µ¿Çâ¿¡ ÀÇÇØ Å©°Ô ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
ÀÌ º¸°í¼¸¦ ±¸ÀÔÇÏ´Â ÀÌÀ¯
- ÀλçÀÌÆ® ÀÖ´Â ºÐ¼® : °í°´ ºÎ¹®, Á¤ºÎ Á¤Ã¥ ¹× »çȸ°æÁ¦ ¿äÀÎ, ¼ÒºñÀÚ ¼±È£, »ê¾÷º° ¹× ±âŸ ÇÏÀ§ ºÎ¹®¿¡ ÁßÁ¡À» µÎ¾î ÁÖ¿ä ¹× ½ÅÈï Áö¿ªÀ» ´Ù·ç´Â »ó¼¼ÇÑ ½ÃÀå °í·Á»çÇ×À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.
- °æÀï ±¸µµ : ¼¼°è ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÑ Àü·«Àû Àü·«À» ÀÌÇØÇϰí ÀûÀýÇÑ Àü·«À¸·Î ½ÃÀå ħÅõ °¡´É¼ºÀ» ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
- ½ÃÀå µ¿Çâ ¹× ÃËÁø¿äÀÎ : µ¿Àû ¿äÀΰú ¸Å¿ì Áß¿äÇÑ ½ÃÀå µ¿Çâ, ±×¸®°í ±×µéÀÌ ÇâÈÄ ½ÃÀå Àü°³¸¦ ¾î¶»°Ô Çü¼ºÇØ ³ª°¡´ÂÁö¸¦ ޱ¸ÇÕ´Ï´Ù.
- ½ÇÇà °¡´ÉÇÑ Á¦¾È : ¿ªµ¿ÀûÀΠȯ°æ¿¡¼ »õ·Î¿î ºñÁî´Ï½º ½ºÆ®¸²°ú ¼öÀÍÀ» ¹ß±¼Çϱâ À§ÇÑ Àü·«Àû °áÁ¤À» ³»¸®±â À§ÇØ ÀλçÀÌÆ®¸¦ Ȱ¿ëÇÕ´Ï´Ù.
- Æø³ÐÀº ÀÌ¿ëÀÚ¿¡ ´ëÀÀ : ½ÅÈï±â¾÷, ¿¬±¸±â°ü, ÄÁ¼³ÅÏÆ®, Áß¼Ò±â¾÷, ´ë±â¾÷¿¡ À¯ÀÍÇÏ°í ºñ¿ë È¿À²ÀûÀÔ´Ï´Ù.
¾î¶² ¿ëµµ·Î »ç¿ëµË´Ï±î?
¾÷°è ¹× ½ÃÀå ÀλçÀÌÆ®, »ç¾÷ ±âȸ Æò°¡, Á¦Ç° ¼ö¿ä ¿¹Ãø, ½ÃÀå ÁøÃâ Àü·«, Áö¸®Àû È®´ë, ¼³ºñ ÅõÀÚ °áÁ¤, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© ¹× ¿µÇâ, ½ÅÁ¦Ç° °³Ã´, °æÀïÀÇ ¿µÇâ
Á¶»ç ¹üÀ§
- ½ÇÀû µ¥ÀÌÅÍ ¹× ¿¹Ãø(2022-2030³â)
- ¼ºÀå ±âȸ, °úÁ¦, °ø±Þ¸Á Àü¸Á, ±ÔÁ¦ Ʋ, °í°´ Çൿ, µ¿Ç⠺м®
- °æÀï Æ÷Áö¼Å´×, Àü·«, ½ÃÀå Á¡À¯À² ºÐ¼®
- ºÎ¹® ¹× °¢±¹À» Æ÷ÇÔÇÑ Áö¿ªÀÇ ¼öÀÍ ¼ºÀå ¹× ¿¹Ãø ºÐ¼®
- ±â¾÷ ÇÁ·ÎÆÄÀϸµ(Àü·«, Á¦Ç°, À繫 »óȲ, ÁÖ¿ä ¹ßÀü µî)
¸ñÂ÷
Á¦1Àå ¼·Ð
- ½ÃÀå °³¿ä
- ½ÃÀåÀÇ Á¤ÀÇ
- Á¶»ç ¹üÀ§
- ½ÃÀå ¼¼ºÐÈ
- ÅëÈ
- ÀüÁ¦Á¶°Ç
- ±âÁØ¿¬µµ ¹× ¿¹Ãø¿¬µµÀÇ Å¸ÀÓ¶óÀÎ
- ÀÌÇØ °ü°èÀÚ¿¡°Ô ÀÖ¾î¼ ÁÖ¿ä ÀÌÁ¡
Á¦2Àå Á¶»ç ¹æ¹ý
Á¦3Àå ÁÖ¿ä ¿ä¾à
Á¦4Àå ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
- Porter's Five Forces ºÐ¼®
- ¾÷°è ¹ë·ùüÀÎ ºÐ¼®
- ¾Ö³Î¸®½ºÆ® º¸±â
Á¦5Àå Á¤¹ÐÀÇ·á ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : Àü°³º°
Á¦6Àå Á¤¹ÐÀÇ·á ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ¿ëµµº°
- ¼¹®
- Á¾¾çÇÐ
- ÁßÃ߽Űæ°è
- ¸é¿ªÇÐ
- ½ÉÀåÇ÷°ü
- ±âŸ
Á¦7Àå Á¤¹ÐÀÇ·á ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°
- ¼¹®
- º´¿ø ¹× Áø·á¼Ò
- Á¦¾à ¿¬±¸½Ã¼³
- ±âŸ
Á¦8Àå Á¤¹ÐÀÇ·á ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : Áö¿ªº°
- ¼¹®
- ºÏ¹Ì
- Àü°³º°
- ¿ëµµº°
- ÃÖÁ¾ »ç¿ëÀÚº°
- ±¹°¡º°
- ³²¹Ì
- Àü°³º°
- ¿ëµµº°
- ÃÖÁ¾ »ç¿ëÀÚº°
- ±¹°¡º°
- À¯·´
- Àü°³º°
- ¿ëµµº°
- ÃÖÁ¾ »ç¿ëÀÚº°
- ±¹°¡º°
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- Àü°³º°
- ¿ëµµº°
- ÃÖÁ¾ »ç¿ëÀÚº°
- ±¹°¡º°
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Àü°³º°
- ¿ëµµº°
- ÃÖÁ¾ »ç¿ëÀÚº°
- ±¹°¡º°
Á¦9Àå °æÀï ȯ°æ ¹× ºÐ¼®
- ÁÖ¿ä ±â¾÷ ¹× Àü·« ºÐ¼®
- ½ÃÀå Á¡À¯À² ºÐ¼®
- ÇÕº´, Àμö, ÇÕÀÇ ¹× Äݶ󺸷¹À̼Ç
- °æÀï ´ë½Ãº¸µå
Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Accenture
- Wipro
- Intel
- GenomOncology LLC
- Precision Medicine Group, LLC.
- Tempus
- Genomind
- Syapse Holdings, Inc.
- Foundation Medicine, Inc.
- 2bPrecise
- Koninklijke Philips NV
- Cision US Inc.
- Genedata AG
- Ariel Precision Medicine
- Integrate.AI Inc.
AJY
The precision medicine software market is estimated to grow at a CAGR of 9.62%, attaining US$3.186 billion by 2030, from US$2.013 billion in 2025.
Precision medicine is a tailored approach to disease prevention and treatment, also known as personalized medicine. It focuses on predicting susceptibility to diseases and preventing disease progression, reducing the trial-and-error nature of drug prescribing and minimizing adverse drug reactions. Precision medicine software serves as a technological platform that provides data-driven, personalized treatment for patients. The rising global incidence of cancer is a significant factor driving the growth of the precision medicine software market during the forecast period.Precision medicine has crucial applications in cancer treatment by offering personalized therapies to patients. Additionally, the increasing integration of artificial intelligence (AI) into healthcare is another major driver of demand for precision medicine software. Countries worldwide are implementing key policies and strategies to enhance the development and integration of AI within the healthcare sector.
Drivers of the Precision Medicine Software Market:
- Advancements in Global AI Technology: The rapid advancement of artificial intelligence technologies is a primary factor fueling the expansion of the precision medicine software market. The AI technology sector has seen substantial growth, driven by innovations in technology. Governments in countries such as the USA, Canada, and India have introduced various policies and initiatives to promote AI development, particularly in healthcare.
For instance, in September 2024, India's Ministry of Health and Family Welfare announced a collaboration with IIT Kanpur and the National Health Authority to develop digital public goods for AI applications in healthcare. Similarly, in April 2024, the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) released its strategic approach to integrating AI into healthcare.
Geographical Trends Shaping the Precision Medicine Software Market:
- Significant Growth in North America: The North American region is expected to hold a substantial share of the precision medicine software market during the forecast period. Countries like the USA and Canada have implemented key strategies to incorporate artificial intelligence into their healthcare systems. The increasing prevalence of chronic diseases, including cancer, further drives demand for precision medicine technologies.
The growing incidence of mental health disorders such as anxiety, depression, and PTSD has created an urgent need for effective treatment options. The COVID-19 pandemic exacerbated these challenges, leading to a surge in demand for mental health services as individuals sought help during heightened stress and uncertainty.In summary, the precision medicine software market is poised for significant growth driven by advancements in AI technology, rising global demand for effective treatments for chronic diseases, supportive governmental initiatives promoting innovation in healthcare technologies, and favorable geographical trends-particularly within North America-that enhance this expanding market landscape.
Reasons for buying this report:-
- Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
- Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
- Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
- Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
- Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.
What do businesses use our reports for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence
Report Coverage:
- Historical data & forecasts from 2022 to 2030
- Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
- Competitive Positioning, Strategies, and Market Share Analysis
- Revenue Growth and Forecast Assessment of segments and regions including countries
- Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)
The Precision Medicine Software Market is segmented and analyzed as follows:
By Deployment
By Application
- Oncology
- Central Nervous System
- Immunology
- Cardiovascular
- Others
By End User
- Hospitals and Clinics
- Pharmaceutical Research Institute
- Others
- By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- Germany
- Spain
- United Kingdom
- France
- Italy
- Others
- Middle East and Africa
- Saudi Arabia
- UAE
- Others
- Asia Pacific
- China
- Japan
- Australia
- India
- Indonesia
- Thailand
- Others
TABLE OF CONTENTS
1. INTRODUCTION
- 1.1. Market Overview
- 1.2. Market Definition
- 1.3. Scope of the Study
- 1.4. Market Segmentation
- 1.5. Currency
- 1.6. Assumptions
- 1.7. Base and Forecast Years Timeline
- 1.8. Key benefits for the stakeholders
2. RESEARCH METHODOLOGY
- 2.1. Research Design
- 2.2. Research Process
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1. Market Drivers
- 4.2. Market Restraints
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. The Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
- 4.4. Industry Value Chain Analysis
- 4.5. Analyst View
5. PRECISION MEDICINE SOFTWARE MARKET BY DEPLOYMENT
- 5.1. Introduction
- 5.2. Cloud
- 5.3. On-Premise
6. PRECISION MEDICINE SOFTWARE MARKET BY APPLICATIONS
- 6.1. Introduction
- 6.2. Oncology
- 6.3. Central Nervous System
- 6.4. Immunology
- 6.5. Cardiovascular
- 6.6. Others
7. PRECISION MEDICINE SOFTWARE MARKET BY END-USER
- 7.1. Introduction
- 7.2. Hospitals and Clinics
- 7.3. Pharmaceutical Research Institute
- 7.4. Others
8. PRECISION MEDICINE SOFTWARE MARKET BY GEOGRAPHY
- 8.1. Introduction
- 8.2. North America
- 8.2.1. By Deployment
- 8.2.2. By Application
- 8.2.3. By End User
- 8.2.4. By Country
- 8.2.4.1. United States
- 8.2.4.2. Canada
- 8.2.4.3. Mexico
- 8.3. South America
- 8.3.1. By Deployment
- 8.3.2. By Application
- 8.3.3. By End User
- 8.3.4. By Country
- 8.3.4.1. Brazil
- 8.3.4.2. Argentina
- 8.3.4.3. Others
- 8.4. Europe
- 8.4.1. By Deployment
- 8.4.2. By Application
- 8.4.3. By End User
- 8.4.4. By Country
- 8.4.4.1. Germany
- 8.4.4.2. Spain
- 8.4.4.3. United Kingdom
- 8.4.4.4. France
- 8.4.4.5. Others
- 8.5. Middle East and Africa
- 8.5.1. By Deployment
- 8.5.2. By Application
- 8.5.3. By End User
- 8.5.4. By Country
- 8.5.4.1. Saudi Arabia
- 8.5.4.2. South Africa
- 8.5.4.3. Others
- 8.6. Asia Pacific
- 8.6.1. By Deployment
- 8.6.2. By Application
- 8.6.3. By End User
- 8.6.4. By Country
- 8.6.4.1. China
- 8.6.4.2. Japan
- 8.6.4.3. Australia
- 8.6.4.4. India
- 8.6.4.5. South Korea
- 8.6.4.6. Indonesia
- 8.6.4.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
- 9.1. Major Players and Strategy Analysis
- 9.2. Market Share Analysis
- 9.3. Mergers, Acquisitions, Agreements, and Collaborations
- 9.4. Competitive Dashboard
10. COMPANY PROFILES
- 10.1. Accenture
- 10.2. Wipro
- 10.3. Intel
- 10.4. GenomOncology LLC
- 10.5. Precision Medicine Group, LLC.
- 10.6. Tempus
- 10.7. Genomind
- 10.8. Syapse Holdings, Inc.
- 10.9. Foundation Medicine, Inc.
- 10.10. 2bPrecise
- 10.11. Koninklijke Philips N.V
- 10.12. Cision US Inc.
- 10.13. Genedata AG
- 10.14. Ariel Precision Medicine
- 10.15. Integrate.AI Inc.